Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$53.10 USD

53.10
4,522,270

+1.90 (3.71%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $53.09 -0.01 (-0.02%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients

by Kinjel Shah

Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.

Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Alnylam (ALNY) incurs wider-than-expected loss and misses sales estimates in the second quarter of 2019.

Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid

by Zacks Equity Research

Regeneron (REGN) tops on Q2 earnings and sales in the second quarter on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.

SNY vs. PFE: Which Stock Is the Better Value Option?

by Zacks Equity Research

SNY vs. PFE: Which Stock Is the Better Value Option?

Are Investors Undervaluing Sanofi (SNY) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss

by Zacks Equity Research

BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.

Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates

by Zacks Equity Research

Emergent's (EBS) earnings miss estimates in the second quarter of 2019 while revenues surpass the mark.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger

by Kinjel Shah

AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.

Company News For Jul 30, 2019

by Zacks Equity Research

Companies in the News Are: MYL, SNY, CTB, MCY.

Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up

by Zacks Equity Research

Sanofi (SNY) beats estimates for second-quarter earnings. Key immunology drug Dupixent drives sales. The company ups its earnings growth expectations for the year.

Christopher Vargas headshot

Buy Merck & Co (MRK) Stock Ahead of Q2 Earnings Report?

by Christopher Vargas

Merck & Co (MRK) is set to report its fiscal 2019 second quarter earnings before the opening bell on July 30th.

AstraZeneca (AZN) Q2 Earnings Top, '19 Product Sales View Up

by Zacks Equity Research

AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)

by Mitchell Moore

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings

by Mitchell Moore

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Kinjel Shah headshot

Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright

by Kinjel Shah

The Zacks Large Cap Pharmaceuticals industry underperforms the sector and S&P 500. However it ranks in the top 19% of more than 250 Zacks industries.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for July 18th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs

by Zacks Equity Research

Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.

Merck's Antibiotic Recarbrio Gets FDA Nod for Infections

by Zacks Equity Research

The FDA approves Merck's (MRK) anti-bacterial injection, MK-7655A, to be marketed as Recarbrio.

AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes

by Zacks Equity Research

AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.

Aimmune Down on Negative ICER Review on Allergy Candidate

by Zacks Equity Research

Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.

SNY or PFE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SNY vs. PFE: Which Stock Is the Better Value Option?

Are Investors Undervaluing Sanofi (SNY) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kinjel Shah headshot

Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

by Kinjel Shah

Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.

FDA Accepts Sanofi's BLA for Myeloma Candidate to Review

by Zacks Equity Research

The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.